Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of piclidenoson in moderate-to-severe plaque psoriasis
2024-519919-34-00Phase 3Authorised
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Piclidenoson with Matching placebo (2 arms). Primary endpoints: PASI 75 response, sPGA 0 or 1 with ≥2-point improvement and 13 more. Planned start Aug 2025; status: authorised.
02
Drugs
piclidenoson
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-519919-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519919-34-00.